HMC-1.2 Human Mast Cell Line

• Each vial contains ≥ 1X10⁶ viable cells.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negative for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.

Research Category
Inflammation & Immunology

Cancer

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.

Cancer Cells

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

HMC-1 cell line was established from a patient with mast cell leukemia. HMC-1 cells are widely used in studies of human mast cell function because they exhibit many key characteristics of tissue mast cells, such as expression of histamine, tryptase, heparin and similar cell surface antigen-profile (1,2). Receptor tyrosine kinase KIT is expressed on mast cells and plays an important role in the proliferation, function and survival of mast cells. Activating mutations in KIT have been linked to dysregulated growth of mast cells and are associated with mast cell tumors and systemic mastocytosis. Two activating point mutations in KIT have been reported in the HMC-1 cell line (3). Both mutations convert the receptor to a constitutively tyrosine phosphorylated and active state, leading to growth factor-independent proliferation.

1. Nilsson, G, et al. (1994) Phenotypic Characterization of the Human Mast-Cell Line HMC-1. Scand. J. Immunol 39: 489-498.
2. Sundstrom, M, et al. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97.
3. Furitsu, T, et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4): 1736-4.

HMC-1.1 (HMC-1(560)) and HMC-1.2 (HMC-1(560,816)) are two variant sublines of the HMC-1 cell line (2). HMC-1.1 possess the V560G mutation, but not the D816V mutation. HMC-1.2 possess both the V560G and D816V mutations and exhibits a higher proliferative rate than HMC-1.1. It has been suggested that the higher proliferative potential of HMC-1.2 may be attributed to the D816V mutation.

Concentration: Please refer to lot specific datasheet.

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.